119 related articles for article (PubMed ID: 4434964)
1. Proceedings: The influence of chronic liver disease on the elimination of d-propranolol, anti-pyrine, and indocyanine green.
Branch RA; James JA; Read AE
Gut; 1974 Oct; 15(10):837-8. PubMed ID: 4434964
[No Abstract] [Full Text] [Related]
2. [Hepatic elimination of indocyanine green and antipyrine in patients with chronic liver disease].
Kuntz HD; Meessen D; May B
Med Welt; 1982 Jun; 33(25):909-10. PubMed ID: 7109938
[No Abstract] [Full Text] [Related]
3. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
Branch RA; James JA; Read AE
Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
[TBL] [Abstract][Full Text] [Related]
4. Beta-adrenoceptor blocking drugs and cytochrome P-450: the influence of propranolol treatment on caffeine, antipyrine, D-glucaric acid and indocyanine green elimination in patients with hepatic disorders.
Traeger A; Horváth T; Rechenbach C; Jávor T
Int J Clin Pharmacol Res; 1986; 6(3):235-9. PubMed ID: 3744626
[TBL] [Abstract][Full Text] [Related]
5. Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.
Hepner GW; Vesell ES; Lipton A; Harvey HA; Wilkinson GR; Schenker S
J Lab Clin Med; 1977 Sep; 90(3):440-56. PubMed ID: 894100
[No Abstract] [Full Text] [Related]
6. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
Hayes PC; Bouchier IA
Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
[TBL] [Abstract][Full Text] [Related]
7. [Different elimination velocity of indocyanine green in liver diseases of various severity].
Brügmann E
Z Gesamte Inn Med; 1973 Sep; 28(17):523-6. PubMed ID: 4767186
[No Abstract] [Full Text] [Related]
8. Proceedings: The relationships between liver volume and the disposition of antipyrine and indocyanine green before and after phenobarbitone treatment.
Branch RA; Halliwell M; Jackson L; Roberts CJ
Br J Pharmacol; 1975 Oct; 55(2):263P. PubMed ID: 1201403
[No Abstract] [Full Text] [Related]
9. Major determinants of drug disposition in chronic liver disease: a study with indocyanine green and antipyrine [proceedings].
Branch RA; James JA; Read AE
Br J Clin Pharmacol; 1975 Aug; 2(4):370P-371P. PubMed ID: 1234003
[No Abstract] [Full Text] [Related]
10. Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
Horváth T; Pár A; Beró T; Kádas I; Fábián C; Jávor T
Acta Med Hung; 1983; 40(4):203-13. PubMed ID: 6674914
[TBL] [Abstract][Full Text] [Related]
11. [Effect of propranolol on the ability of the liver to metabolize drugs in patients with hypertension].
Adamska-Dyniewska H; Gajewska B
Kardiol Pol; 1979; 22(1):7-11. PubMed ID: 423420
[No Abstract] [Full Text] [Related]
12. Beta-adrenergic blockade affects initial drug distribution due to decreased cardiac output and altered blood flow distribution.
Avram MJ; Krejcie TC; Henthorn TK; Niemann CU
J Pharmacol Exp Ther; 2004 Nov; 311(2):617-24. PubMed ID: 15197245
[TBL] [Abstract][Full Text] [Related]
13. [Chromodiagnosis of the liver: interpretation of the elimination curve of indocyanine green dye (Wofaverdin)].
Seifert A; Ehrke D; Balzer H
Z Gesamte Inn Med; 1968 Sep; 23(17):527-31. PubMed ID: 5728034
[No Abstract] [Full Text] [Related]
14. [Liver dye metabolism and constitutional indocyanine green retention syndrome in Japan (author's transl)].
Shibata H; Toyama K
Leber Magen Darm; 1976 Dec; 6(6):330-4. PubMed ID: 1018575
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the hepatic excretion mechanism of indocyanine green in patients with liver disease. II. Two-compartment analysis for in vivo kinetics.
Nakagawa S; Araki K; Nagashima H
Kumamoto Med J; 1977 Mar; 30(1):1-8. PubMed ID: 611312
[No Abstract] [Full Text] [Related]
16. Half-life time or clearance of indocyanine green in patients with liver disease.
Gilmore IT; Marigold JH; Thompson RP
Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
[TBL] [Abstract][Full Text] [Related]
17. [Correlations of kinetics of antipyrine, indocyanine green and bromosulfophthalein in healthy subjects and in patients with cardiovascular diseases].
Adamska-Dyniewska H; Kowalczyk L
Pol Tyg Lek; 1978 Jul; 33(29):1143-5. PubMed ID: 704415
[No Abstract] [Full Text] [Related]
18. Influence of azathioprine on hepatic reserve in chronic active liver disease.
Rikkers L; Sherlock S
Gut; 1975 Mar; 16(3):214-9. PubMed ID: 1123176
[TBL] [Abstract][Full Text] [Related]
19. Indocyanine green clearance following single and chronic cimetidine doses.
MacKichan JJ; Schaal SF; Stine RA; Boudoulas H
Res Commun Chem Pathol Pharmacol; 1984 May; 44(2):323-6. PubMed ID: 6739959
[TBL] [Abstract][Full Text] [Related]
20. Proceedings: Antipyrine, lingocaine and paracetamol metabolism in chronic liver disease.
Forrest JA; Finlayson ND; Adjepon-Yamoah KK; Prescott LF
Gut; 1975 Oct; 16(10):828-9. PubMed ID: 1205294
[No Abstract] [Full Text] [Related]
[Next] [New Search]
